Analysts think SLRX stock price could increase by 704%
Jul 31, 2024, 6:26 AM
-47.88%
What does SLRX do
Salarius Pharmaceuticals, Inc., a clinical-stage oncology company based in Houston, Texas, specializes in developing treatments for cancers with high unmet medical needs, including a focus on dysregulated gene expression. The company, which went public in 2015, is advancing a portfolio that features seclidemstat for pediatric cancers and sarcomas, and SP-3164, a molecular glue degrader.
3 analysts think SLRX stock price will increase by 703.64%. The current median analyst target is $26.52 compared to a current stock price of $3.30. The lowest analysts target is $26.26 and the highest analyst target is $27.30.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
